Hepatitis C is a major health burden, with nearly 12,000 new cases reported in Canada alone in 2019. Despite significant progress in understanding the pathology of the disease and developing effective antiviral drugs, a preventive vaccine remains elusive. Recent insights into the architecture of the virus and its mechanisms of infection have prompted hypotheses about possible vaccine strategies, particularly involving the use of monoclonal antibodies (mAb) neutralizing the E1E2 glycoprotein complex.
This site was created as part of the Pharm 498 project. The goal of the project is to create a unified registry of antibodies and mAbs known to bind to different sites in the E1 E2 protein.
Currently, this project aims to focus only on human mAbs and Abs. This site is for educational purposes only.